STAA Stock Analysis: STAAR Surgical | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 1.393m USD | 12M Return: 55.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 18.0M
Qual. Beats: 0
Rev. Trend: -65.9%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
STAAR Surgical Company (NASDAQ: STAA) is a Lake Forest, California-based medical device company founded in 1982 that designs, develops, manufactures, and markets phakic intraocular lenses used in refractive surgery. Its core product line is the Implantable Collamer Lens (ICL) family, which includes the EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL, used to treat myopia, hyperopia, astigmatism, and presbyopia. The company operates in the Health Care Supplies sub-industry, supplying ophthalmic surgeons, vision and surgical centers, hospitals, and distributors across more than a dozen countries, with direct sales in markets such as the U.S., Japan, Germany, Spain, and Singapore, and distributor-based reach into China, Korea, India, and other international markets.
STAARs phakic ICLs represent an alternative to laser-based corneal refractive procedures like LASIK, as the lens is implanted in front of the eyes natural lens rather than reshaping corneal tissue. The company relies on a hybrid sales model, combining its own sales force in key markets with independent distributors in regions where direct presence is limited, which is a common go-to-market approach among small-cap medical device makers in the ophthalmology space.
- EVO ICL adoption in US accelerates
- China refractive market weakness pressures Asia sales
- LASIK competition caps refractive procedure market share
| Net Income: -21.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.12 > 0.02 and ΔFCF/TA -9.20 > 1.0 |
| NWC/Revenue: 86.58% < 20% (prev 92.48%; Δ -5.90% < -1%) |
| CFO/TA -0.11 > 3% & CFO -50.2m > Net Income -21.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (50.9m) vs 12m ago 3.15% < -2% |
| Gross Margin: 76.43% > 18% (prev 74.00%; Δ 2.43% > 0.5%) |
| Asset Turnover: 63.93% > 50% (prev 61.03%; Δ 2.89% > 0%) |
| Interest Coverage Ratio: -1.85 > 6 (EBIT TTM -12.7m / Interest Expense TTM 6.85m) |
| A: 0.56 (Total Current Assets 312.4m - Total Current Liabilities 61.0m) / Total Assets 451.1m |
| B: -0.32 (Retained Earnings -142.8m / Total Assets 451.1m) |
| C: -0.03 (EBIT TTM -12.7m / Avg Total Assets 454.2m) |
| D: 3.57 (Book Value of Equity 352.4m / Total Liabilities 98.8m) |
| Altman-Z'' = 6.18 = AAA |
| DSRI: 1.93 (Receivables 85.7m/42.7m, Revenue 290.4m/279.1m) |
| GMI: 0.97 (GM 74.00% / 76.43%) |
| AQI: 1.57 (AQ_t 0.09 / AQ_t-1 0.05) |
| SGI: 1.04 (Revenue 290.4m / 279.1m) |
| TATA: 0.06 (NI -21.0m - CFO -50.2m) / TA 451.1m) |
| Beneish M = -1.92 (Cap -4..+1) = B |
As of July 11, 2026, the stock is trading at USD 27.76 with a total of 360,584 shares traded. Over the past week, the price has changed by -0.11%, over one month by -5.35%, over three months by +4.99% and over the past year by +55.87%.
Current recommended Stop Loss: 26.10 (which is 6% or 1.3 ATR below the current price).
STAAR Surgical has received a consensus analysts rating of 3.29. Therefore, it is recommended to hold STAA.
- StrongBuy: 3
- Buy: 0
- Hold: 10
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 29.7 | 6.9% |
P/E Forward = 121.9512
P/S = 4.7958
P/B = 3.9775
P/EG = 0.7622
Revenue TTM = 290.4m USD
EBIT TTM = -12.7m USD
EBITDA TTM = -4.11m USD
Long Term Debt = 31.2m USD (estimated: total debt 37.3m - short term 6.10m)
Short Term Debt = 6.10m USD (from shortTermDebt, last quarter)
Debt = 37.3m USD (from shortLongTermDebtTotal, last quarter) (leases 37.3m already included)
Net Debt = -126.6m USD (calculated: Debt 37.3m - CCE 163.9m)
Enterprise Value = 1.27b USD (1.39b + Debt 37.3m - CCE 163.9m)
Interest Coverage Ratio = -1.85 (Ebit TTM -12.7m / Interest Expense TTM 6.85m)
EV/FCF = -23.02x (Enterprise Value 1.27b / FCF TTM -55.0m)
FCF Yield = -4.34% (FCF TTM -55.0m / Enterprise Value 1.27b)
FCF Margin = -18.94% (FCF TTM -55.0m / Revenue TTM 290.4m)
Net Margin = -7.24% (Net Income TTM -21.0m / Revenue TTM 290.4m)
Gross Margin = 76.43% ((Revenue TTM 290.4m - Cost of Revenue TTM 68.4m) / Revenue TTM)
Gross Margin QoQ = 72.20% (prev 75.68%)
Tobins Q-Ratio = 2.81 (Enterprise Value 1.27b / Total Assets 451.1m)
Interest Expense / Debt = 18.37% (Interest Expense 6.85m / Debt 37.3m)
Taxrate = 36.65% (3.01m / 8.22m)
NOPAT = -8.05m (EBIT -12.7m * (1 - 36.65%)) [loss with tax shield]
Current Ratio = 5.12 (Total Current Assets 312.4m / Total Current Liabilities 61.0m)
Debt / Equity = 0.11 (Debt 37.3m / totalStockholderEquity, last quarter 352.4m)
Debt / EBITDA = 30.83 (negative EBITDA) (Net Debt -126.6m / EBITDA -4.11m)
Debt / FCF = 2.30 (negative FCF - burning cash) (Net Debt -126.6m / FCF TTM -55.0m)
Total Stockholder Equity = 346.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.63% (Net Income -21.0m / Total Assets 451.1m)
RoE = -6.07% (Net Income TTM -21.0m / Total Stockholder Equity 346.7m)
RoCE = -3.36% (EBIT -12.7m / Capital Employed (Equity 346.7m + L.T.Debt 31.2m))
RoIC = -2.11% (negative operating profit) (NOPAT -8.05m / Invested Capital 381.7m)
WACC = 8.27% (E(1.39b)/V(1.43b) * Re(8.18%) + D(37.3m)/V(1.43b) * Rd(18.37%) * (1-Tc(0.37)))
Discount Rate = 8.18% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 44.95 | Cagr: 1.48%
[DCF] Fair Price = unknown (Cash Flow -55.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.59 | # QB: 0
Revenue Correlation: -65.91 | Revenue CAGR: -10.25% | SUE: 1.18 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.23 | Chg30d=+15.05% | Revisions=+57% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.16 | Chg30d=-9.81% | Revisions=+50% | Analysts=8
EPS current Year (2026-12-31): EPS=0.74 | Chg30d=+33.07% | Revisions=+29% | GrowthEPS=+542.3% | GrowthRev=+39.6%
EPS next Year (2027-12-31): EPS=0.99 | Chg30d=+28.25% | Revisions=+62% | GrowthEPS=+34.1% | GrowthRev=+7.6%
[Analyst] Revisions Ratio: +74% (up=15, down=1)